It is possible that prescriptions were not filled or that patients were not compliant with prescribed dosing frequencies
As a GLP-1 receptor agonist, semaglutide binds to GLP-1 receptors distributed throughout the gastrointestinal tract, pancreas, and central nervous system
What are your thoughts on those applications, and is this something where we need to rethink our relationship with medicine, or do you think there are risks
Key points: In clinical trials, tirzepatide (Mounjaro) produced roughly double the average weight loss of liraglutide (Saxenda), though these were separate trials with different durations Tirzepatide at the 15 mg dose produced approximately 21% average weight loss over 72 weeks Liraglutide 3.0 mg produced approximately 8% average weight loss over 56 weeks Real-world data from Second Nature shows even greater results (22.1%) when tirzepatide is combined with behavioural support Side effects and tolerability Both medications share a similar side-effect profile, predominantly affecting the gastrointestinal tract
Similarly, kidney issues can affect your body's ability to concentrate urine, leading to increased fluid loss and, consequently, a heightened sense of thirst
However, cost remains a major barrier